查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1785837

双胍类药物的全球市场

Biguanides
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球双胍类药物市场规模将达到 59 亿美元

全球双胍类药物市场规模预计在2024年为51亿美元，预计到2030年将达到59亿美元，在分析期内（2024-2030年）的复合年增长率为2.5%。Metformin是本报告分析的细分市场之一，预计其复合年增长率为3.1%，到分析期结束时将达到35亿美元。苯乙双胍细分市场在分析期间的复合年增长率预计为1.7%。

美国市场规模估计为 14 亿美元，中国市场预计复合年增长率为 5.0%

美国双胍类药物市场规模预计在2024年达到14亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到11亿美元，在2024-2030年的分析期间内，复合年增长率为5.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为0.9%和1.9%。在欧洲，预计德国市场的复合年增长率为1.4%。

全球双胍类药物市场－主要趋势与驱动因素摘要

为什么双胍类是糖尿病和抗生素治疗的重要组成部分？

双胍类药物主要用于治疗第2型糖尿病，因其能够降低血糖值并改善胰岛素敏感性，一直是糖尿病管理的基石。Metformin是处方最广泛的双胍类药物，因其促进週边葡萄糖摄取并降低肝臟葡萄糖生成的作用而得到世界公认。随着全球第二型糖尿病和代谢紊乱的盛行率不断上升，医疗保健专业人员正在寻求经济高效且可靠的治疗方法，这推动了对双胍类药物的需求稳步增长。此外，双胍类药物在糖尿病治疗之外也展现出广阔的前景，新兴研究显示其在抗衰老、癌症治疗和心血管疾病预防方面具有潜在的应用前景。

双胍类药物除了在METABOLIC INC.健康中发挥作用外，还因其抗菌特性而被广泛应用，尤其是在消毒剂和防腐剂中。洛赫西定是一种双胍类化合物，是医用防腐剂、口腔卫生产品和外科消毒剂的关键成分。它对细菌、真菌和病毒具有广泛的抗菌活性，使其成为医院感染控制和个人护理应用的必需品。随着人们对抗生素抗药性的担忧日益加剧，製药、医疗保健和消费者卫生市场对双胍类等替代抗菌解决方案的需求日益增长。双胍类药物仍然是代谢疾病管理和感染预防的关键组成部分，目前正在进行的临床研究正在探索新的治疗应用。

科技进步如何增强双胍类疗法？

製剂和药物输送系统的创新显着提高了双胍类药物的疗效、生物有效性和安全性。该领域最显着的进展之一是Metformin缓释性(ER) 製剂的开发，该製剂通过减少胃肠道副作用和最大限度地减少多剂量的需要，提高了患者的服药依从性。这些製剂可增强药物吸收并提供更稳定的血糖控制，使其成为长期糖尿病管理的首选方案。此外，双胍类药物与钠-葡萄糖协同共同输送体蛋白-2 (SGLT2) 抑制剂或Dipeptidyl Peptidase-4 (DPP-4) 抑制剂联合治疗的研究正在改善复杂代谢疾病患者的预后。

另一项重大突破是双胍类药物在癌症和神经退化性疾病等新治疗领域的探索。最近的研究表明，Metformin透过抑制细胞能量代谢和抑制肿瘤生长而具有抗癌特性。此外，临床前研究表明Metformin可能具有神经保护特性，并可能在减缓阿兹海默症和其他神经退化性疾病的进展方面发挥作用。在抗菌剂领域，基于奈米颗粒的递送系统的进步提高了洛赫西定在预防医院内感染和改善创伤治疗的有效性。随着製药和生技公司继续在研发方面投入，双胍类药物有望扩展到新的医疗应用领域，并在现代医学中发挥越来越重要的作用。

哪些行业趋势将推动双胍类药物市场的成长？

全球双胍类药物市场正稳步增长，这得益于糖尿病患病率的上升、抗菌解决方案需求的不断增长以及新兴治疗领域应用的不断拓展。影响市场发展的最重要趋势之一是第2型糖尿病患者的快速成长，尤其是在新兴经济体，生活方式的改变和都市化导致代谢紊乱的发生率居高不下。随着各国政府和医疗机构将糖尿病管理置于优先地位，Metformin因其价格实惠且疗效确切，仍是首选药物。此外，预防性医疗保健的日益重视也促进了筛检和早期诊断的增多，进一步推动了对双胍类药物的需求。

影响市场的另一个关键趋势是人们越来越重视医疗保健和消费者卫生领域的感染控制。 COVID-19 疫情提高了人们对抗菌素抗药性和有效消毒剂需求的认识，导致医院、牙科诊所和个人卫生产品中双胍类消毒剂（如洛赫西定）的使用增加。此外，远端医疗和网路药局的扩张改善了双胍类药物的可近性，确保了市场的持续成长。随着研究人员开发出基于基因和代谢特征优化治疗的标靶治疗，双胍类药物在个人化医疗（尤其是精准糖尿病护理）中的探索也越来越受到关注。随着对创新且具成本效益的医疗保健解决方案的需求持续增长，双胍类市场预计将扩展到多种治疗和预防应用。

影响双胍类药物市场未来发展的关键成长动力有哪些？

双胍类药物市场的成长受到多种因素的推动，包括糖尿病盛行率的上升、药物研发投入的增加以及在糖尿病以外治疗领域的应用不断扩大。其中一个主要的成长要素是持续的全球糖尿病疫情，预计2023年将影响超过5.37亿成年人。Metformin价格实惠且在临床上长期取得成功，使其成为糖尿病管理策略的关键组成部分，尤其是在难以获得先进疗法的新兴市场。此外，製药公司正在探索新的药物组合和下一代双胍类药物类似物，以提高疗效并最大程度地减少副作用。

影响市场的另一个关键驱动因素是对抗菌和感染控制解决方案日益增长的需求。随着医院获得性感染 (HAI) 成为重大公共卫生风险，对洛赫西定类抗菌剂和消毒剂的需求也日益增长。此外，人们对抗菌素抗药性的认识不断提高，推动了对能够增强抗抗药性病原体功效的双胍类衍生物的研究。双胍类药物在肿瘤学、神经保护和长寿研究中的潜在作用也激发了生物技术和製药公司的兴趣，带来了新的投资机会。随着科学进步不断开发新的治疗应用，以及监管机构支持扩大适应症，双胍类药物市场正在经历持续成长，巩固了其在代谢和抗菌药物领域的重要性。

部分

类型（Metformin、苯乙双胍）、分销管道（零售药局分销管道、医院分销管道、其他分销管道）

受访公司范例

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

人工智慧集成

利用检验的专家内容和 AI 工具转变您的市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP29554

Global Biguanides Market to Reach US$5.9 Billion by 2030

The global market for Biguanides estimated at US$5.1 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Metformin, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Phenformin segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.0% CAGR

The Biguanides market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Biguanides Market - Key Trends & Drivers Summarized

Why Are Biguanides a Critical Component in Diabetes and Antimicrobial Treatments?

Biguanides, a class of medications primarily used to treat type 2 diabetes, have remained a cornerstone of diabetes management due to their effectiveness in lowering blood glucose levels and improving insulin sensitivity. Metformin, the most widely prescribed biguanide, has gained global recognition for its role in reducing hepatic glucose production while enhancing peripheral glucose uptake. With the increasing prevalence of type 2 diabetes and metabolic disorders worldwide, the demand for biguanides continues to rise as healthcare providers seek cost-effective and reliable treatment options. Additionally, biguanides have shown promise beyond diabetes treatment, with emerging research suggesting potential applications in anti-aging, cancer therapy, and cardiovascular disease prevention.

Beyond their role in metabolic health, biguanides are also widely used for their antimicrobial properties, particularly in disinfectants and antiseptics. Chlorhexidine, a biguanide-based compound, is a key ingredient in medical-grade antiseptics, oral hygiene products, and surgical disinfectants. Its broad-spectrum antimicrobial activity against bacteria, fungi, and viruses has made it indispensable in hospital infection control and personal care applications. As concerns about antibiotic resistance grow, the demand for alternative antimicrobial solutions like biguanides is expanding across pharmaceutical, healthcare, and consumer hygiene markets. With ongoing clinical research exploring new therapeutic uses, biguanides are positioned to remain a vital component of both metabolic disease management and infection prevention.

How Are Technological Advancements Enhancing Biguanide-Based Treatments?

Innovations in pharmaceutical formulation and drug delivery systems are significantly improving the efficacy, bioavailability, and safety profile of biguanide-based treatments. One of the most notable advancements in this field is the development of extended-release (ER) metformin formulations, which offer better patient adherence by reducing gastrointestinal side effects and minimizing the need for multiple daily doses. These formulations enhance drug absorption and provide more stable glucose control, making them a preferred option for long-term diabetes management. Additionally, research into combination therapies that pair biguanides with sodium-glucose co-transporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is driving improved treatment outcomes for patients with complex metabolic conditions.

Another major breakthrough is the exploration of biguanides in new therapeutic areas, including oncology and neurodegenerative diseases. Recent studies have suggested that metformin possesses anti-cancer properties by inhibiting cellular energy metabolism and reducing tumor growth. Additionally, preclinical research indicates that biguanides may have neuroprotective effects, potentially playing a role in delaying the progression of Alzheimer’s disease and other neurodegenerative disorders. In the antimicrobial sector, advancements in nanoparticle-based delivery systems are enhancing the effectiveness of chlorhexidine in preventing hospital-acquired infections and improving wound healing. As pharmaceutical and biotech companies continue to invest in research and development, biguanide-based treatments are expected to expand into new medical applications, reinforcing their relevance in modern medicine.

Which Industry Trends Are Driving Growth in the Biguanides Market?

The global biguanides market is experiencing steady growth due to rising diabetes prevalence, increasing demand for antimicrobial solutions, and expanding applications in emerging therapeutic fields. One of the most influential trends shaping the market is the surge in type 2 diabetes cases, particularly in developing economies where lifestyle changes and urbanization have led to a higher incidence of metabolic disorders. With governments and healthcare organizations prioritizing diabetes management, metformin remains a first-line therapy due to its affordability and proven efficacy. Additionally, the growing emphasis on preventive healthcare has led to increased screening and early diagnosis, further driving demand for biguanide-based treatments.

Another key trend influencing the market is the rising focus on infection control in healthcare and consumer hygiene. The COVID-19 pandemic heightened awareness of antimicrobial resistance and the need for effective disinfectants, leading to increased use of biguanide-based antiseptics like chlorhexidine in hospitals, dental care, and personal hygiene products. Moreover, the expansion of telemedicine and e-pharmacies has improved access to biguanide medications, ensuring continued market growth. The exploration of biguanides in personalized medicine, particularly in precision diabetes care, is also gaining traction as researchers develop targeted therapies that optimize treatment based on genetic and metabolic profiles. As the demand for innovative and cost-effective healthcare solutions continues to rise, the biguanides market is expected to expand across multiple therapeutic and preventive applications.

What Are the Key Growth Drivers Shaping the Future of the Biguanides Market?

The growth in the biguanides market is driven by several factors, including increasing diabetes prevalence, rising investments in drug research, and expanding applications in non-diabetes therapeutic areas. One of the primary growth drivers is the ongoing global diabetes epidemic, with over 537 million adults estimated to have diabetes in 2023. The affordability and long-standing clinical success of metformin make it a critical component of diabetes management strategies, particularly in emerging markets with limited access to advanced therapies. Additionally, pharmaceutical companies are exploring novel drug combinations and next-generation biguanide analogs to enhance therapeutic efficacy and minimize side effects.

Another key driver shaping the market is the growing need for antimicrobial and infection control solutions. With hospital-acquired infections (HAIs) posing a significant public health risk, the demand for chlorhexidine-based antiseptics and disinfectants continues to rise. Furthermore, the increasing awareness of antimicrobial resistance has prompted research into biguanide derivatives with enhanced efficacy against drug-resistant pathogens. The potential role of biguanides in oncology, neuroprotection, and longevity research is also driving interest from biotech and pharmaceutical firms, leading to new investment opportunities. As scientific advancements continue to unlock new therapeutic applications and regulatory agencies support expanded indications, the biguanides market is poised for sustained growth, solidifying its importance in both metabolic and antimicrobial medicine.

SCOPE OF STUDY:

The report analyzes the Biguanides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Metformin, Phenformin); Distribution Channel (Retail Pharmacies Distribution Channel, Hospitals Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biguanides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Biguanides as a First-Line Therapeutic Class
    • Growing Demand for Cost-Effective Antidiabetic Drugs Drives Widespread Use of Metformin-Based Biguanides
    • Increased Focus on Metabolic Health and Pre-Diabetes Management Expands Addressable Market Opportunity for Biguanide Compounds
    • Scientific Advancements in Repurposing Biguanides for Cancer, Aging, and Cardiovascular Health Strengthen Long-Term Growth Prospects
    • Regulatory Endorsement of Metformin as a Gold-Standard Treatment Drives Continued Global Adoption
    • Emerging Research on Biguanides in Geroprotection and Longevity Science Spurs New Therapeutic Applications
    • Surge in Demand for Antimicrobial Agents Drives Biguanide Usage in Hospital-Grade Disinfectants and Antiseptics
    • Expansion of Personal Hygiene and Surface Disinfection Markets Strengthens the Business Case for Biguanide-Based Biocides
    • Growing Emphasis on Infection Control in Healthcare Facilities Fuels Demand for Biguanide Antiseptics Like Chlorhexidine
    • Interest in Combination Therapies and Drug Synergies Enhances Use of Biguanides in Multimodal Treatment Regimens
    • Rising Geriatric Population and Polypharmacy Trends Sustain Long-Term Demand for Well-Tolerated Biguanide Drugs
    • Low Cost and High Therapeutic Index of Biguanides Support Their Role in Essential Drug Lists and Public Health Programs
    • Emerging Interest in Biguanides for Weight Management and Insulin Sensitivity Strengthens Consumer and Clinical Demand
    • Increasing Pharmaceutical R&D Investments Drive Innovation in Modified-Release and Combination Formulations of Biguanides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biguanides Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Metformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phenformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION